FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204019269> ?p ?o ?g. }

• W3204019269 endingPage "1518" @default.
• W3204019269 startingPage "1510" @default.
• W3204019269 abstract "The safety and effectiveness of live virus vaccines, such as the varicella-zoster vaccine, are unknown in patients with inflammatory diseases receiving immunomodulatory therapy such as tumor necrosis factor inhibitors (TNFis).To evaluate the safety and immunogenicity of the live attenuated zoster vaccine (ZVL) in patients receiving TNFis.Randomized, blinded, placebo-controlled trial. (ClinicalTrials.gov: NCT02538341).Academic and community-based rheumatology, gastroenterology, and dermatology practices.Adults aged 50 years or older receiving TNFis for any indication.Random assignment to ZVL versus placebo.Glycoprotein enzyme-linked immunosorbent assay (gpELISA) and enzyme-linked immunosorbent spot (ELISpot) from serum and peripheral blood mononuclear cells measured at baseline and 6 weeks after vaccination. Suspected varicella infection or herpes zoster was clinically assessed using digital photographs and polymerase chain reaction on vesicular fluid.Between March 2015 and December 2018, 617 participants were randomly assigned in a 1:1 ratio to receive ZVL (n = 310) or placebo (n = 307) at 33 centers. Mean age was 62.7 years (SD, 7.5); 66.1% of participants were female, 90% were White, 8.2% were Black, and 5.9% were Hispanic. The most common TNFi indications were rheumatoid arthritis (57.6%) and psoriatic arthritis (24.1%); TNFi medications were adalimumab (32.7%), infliximab (31.3%), etanercept (21.2%), golimumab (9.1%), and certolizumab (5.7%). Concomitant therapies included methotrexate (48.0%) and oral glucocorticoids (10.5%). Through week 6, no cases of confirmed varicella infection were found; cumulative incidence of varicella infection or shingles was 0.0% (95% CI, 0.0% to 1.2%). At 6 weeks, compared with baseline, the mean increases in geometric mean fold rise as measured by gpELISA and ELISpot were 1.33 percentage points (CI, 1.17 to 1.51 percentage points) and 1.39 percentage points (CI, 1.07 to 1.82 percentage points), respectively.Potentially limited generalizability to patients receiving other types of immunomodulators.This trial informs safety concerns related to use of live virus vaccines in patients receiving biologics.The National Institute of Arthritis and Musculoskeletal and Skin Diseases and the American College of Rheumatology." @default.
• W3204019269 created "2021-10-11" @default.
• W3204019269 creator A5000754711 @default.
• W3204019269 creator A5006070255 @default.
• W3204019269 creator A5009710595 @default.
• W3204019269 creator A5010046631 @default.
• W3204019269 creator A5016172583 @default.
• W3204019269 creator A5018821990 @default.
• W3204019269 creator A5022848171 @default.
• W3204019269 creator A5036616134 @default.
• W3204019269 creator A5040930198 @default.
• W3204019269 creator A5044067217 @default.
• W3204019269 creator A5046013095 @default.
• W3204019269 creator A5061318058 @default.
• W3204019269 creator A5064792562 @default.
• W3204019269 creator A5073339502 @default.
• W3204019269 creator A5077900453 @default.
• W3204019269 creator A5081176712 @default.
• W3204019269 creator A5082669130 @default.
• W3204019269 creator A5086105954 @default.
• W3204019269 creator A5090731148 @default.
• W3204019269 date "2021-11-01" @default.
• W3204019269 modified "2023-10-10" @default.
• W3204019269 title "The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy" @default.
• W3204019269 cites W1991831820 @default.
• W3204019269 cites W2059539909 @default.
• W3204019269 cites W2075994714 @default.
• W3204019269 cites W2086658590 @default.
• W3204019269 cites W2113550278 @default.
• W3204019269 cites W2114386527 @default.
• W3204019269 cites W2130875526 @default.
• W3204019269 cites W2131041950 @default.
• W3204019269 cites W2132828342 @default.
• W3204019269 cites W2146890931 @default.
• W3204019269 cites W2297608701 @default.
• W3204019269 cites W2310571746 @default.
• W3204019269 cites W2769857587 @default.
• W3204019269 cites W2791726267 @default.
• W3204019269 cites W2792992921 @default.
• W3204019269 cites W2884143678 @default.
• W3204019269 cites W2971217817 @default.
• W3204019269 cites W2998003890 @default.
• W3204019269 cites W3024036137 @default.
• W3204019269 doi "https://doi.org/10.7326/m20-6928" @default.
• W3204019269 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34570596" @default.
• W3204019269 hasPublicationYear "2021" @default.
• W3204019269 type Work @default.
• W3204019269 sameAs 3204019269 @default.
• W3204019269 citedByCount "13" @default.
• W3204019269 countsByYear W32040192692021 @default.
• W3204019269 countsByYear W32040192692022 @default.
• W3204019269 countsByYear W32040192692023 @default.
• W3204019269 crossrefType "journal-article" @default.
• W3204019269 hasAuthorship W3204019269A5000754711 @default.
• W3204019269 hasAuthorship W3204019269A5006070255 @default.
• W3204019269 hasAuthorship W3204019269A5009710595 @default.
• W3204019269 hasAuthorship W3204019269A5010046631 @default.
• W3204019269 hasAuthorship W3204019269A5016172583 @default.
• W3204019269 hasAuthorship W3204019269A5018821990 @default.
• W3204019269 hasAuthorship W3204019269A5022848171 @default.
• W3204019269 hasAuthorship W3204019269A5036616134 @default.
• W3204019269 hasAuthorship W3204019269A5040930198 @default.
• W3204019269 hasAuthorship W3204019269A5044067217 @default.
• W3204019269 hasAuthorship W3204019269A5046013095 @default.
• W3204019269 hasAuthorship W3204019269A5061318058 @default.
• W3204019269 hasAuthorship W3204019269A5064792562 @default.
• W3204019269 hasAuthorship W3204019269A5073339502 @default.
• W3204019269 hasAuthorship W3204019269A5077900453 @default.
• W3204019269 hasAuthorship W3204019269A5081176712 @default.
• W3204019269 hasAuthorship W3204019269A5082669130 @default.
• W3204019269 hasAuthorship W3204019269A5086105954 @default.
• W3204019269 hasAuthorship W3204019269A5090731148 @default.
• W3204019269 hasConcept C126322002 @default.
• W3204019269 hasConcept C142724271 @default.
• W3204019269 hasConcept C159654299 @default.
• W3204019269 hasConcept C17991360 @default.
• W3204019269 hasConcept C203014093 @default.
• W3204019269 hasConcept C204787440 @default.
• W3204019269 hasConcept C2522874641 @default.
• W3204019269 hasConcept C27081682 @default.
• W3204019269 hasConcept C2777138892 @default.
• W3204019269 hasConcept C2777226972 @default.
• W3204019269 hasConcept C2777575956 @default.
• W3204019269 hasConcept C2779001537 @default.
• W3204019269 hasConcept C2780132546 @default.
• W3204019269 hasConcept C2780473352 @default.
• W3204019269 hasConcept C2780801004 @default.
• W3204019269 hasConcept C71924100 @default.
• W3204019269 hasConcept C90924648 @default.
• W3204019269 hasConceptScore W3204019269C126322002 @default.
• W3204019269 hasConceptScore W3204019269C142724271 @default.
• W3204019269 hasConceptScore W3204019269C159654299 @default.
• W3204019269 hasConceptScore W3204019269C17991360 @default.
• W3204019269 hasConceptScore W3204019269C203014093 @default.
• W3204019269 hasConceptScore W3204019269C204787440 @default.
• W3204019269 hasConceptScore W3204019269C2522874641 @default.
• W3204019269 hasConceptScore W3204019269C27081682 @default.
• W3204019269 hasConceptScore W3204019269C2777138892 @default.

• next